All Stories

  1. Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: Effects in wild type and human A30P mutant α-synuclein mice
  2. MAPT p.V363I mutation
  3. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease
  4. Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia
  5. LRP10 in α-synucleinopathies
  6. Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer's disease
  7. High prevalence of focal and multi-focal somatic genetic variants in the human brain
  8. Frequency and signature of somatic variants in 1461 human brain exomes
  9. The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target
  10. The impact of stapling technique and surgeon specialism on anastomotic failure after right-sided colorectal resection: an international multicentre, prospective audit
  11. CXCR4 involvement in neurodegenerative diseases
  12. Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies
  13. Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains
  14. Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies
  15. Gene expression analysis reveals chronic low level exposure to the pesticide diazinon affects psychological disorders gene sets in the adult rat
  16. Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias
  17. Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease
  18. Regional levels of physiological α-synuclein are directly associated with Lewy body pathology
  19. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection An international audit by ESCP and S-ECCO
  20. SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease
  21. Neuronal Loss and Α-Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies
  22. The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit
  23. Trichloroethylene-induced formic aciduria in the male C57 Bl/6 mouse
  24. Erratum to: Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains
  25. Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains
  26. Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies
  27. Sirtuin-2 Protects Neural Cells from Oxidative Stress and Is Elevated in Neurodegeneration
  28. Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource
  29. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases
  30. Extended post-mortem delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: a study from the Brains for Dementia Research Network Neuropathology Study Group, UK
  31. Anatomic Connections of the Subgenual Cingulate Region
  32. Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations
  33. Telomerase Activity is Downregulated Early During Human Brain Development
  34. Development of passive CLARITY and immunofluorescent labelling of multiple proteins in human cerebellum: understanding mechanisms of neurodegeneration in mitochondrial disease
  35. A Low Mortality, High Morbidity Reduced Intensity Status Epilepticus (RISE) Model of Epilepsy and Epileptogenesis in the Rat
  36. Mechanism for the acute effects of organophosphate pesticides on the adult 5-HT system
  37. Exome sequencing in dementia with Lewy bodies
  38. Mitochondrial DNA Depletion in Respiratory Chain-Deficient Parkinson Disease Neurons
  39. Low-level repeated exposure to diazinon and chlorpyrifos decrease anxiety-like behaviour in adult male rats as assessed by marble burying behaviour
  40. Voxel-based analysis in neuroferritinopathy expands the phenotype and determines radiological correlates of disease severity
  41. Erratum to: Diquat causes caspase-independent cell death in SH-SY5Y cells by production of ROS independently of mitochondria
  42. Changes to the lateral geniculate nucleus in Alzheimer's disease but not dementia with Lewy bodies
  43. Neural Differentiation Modulates the Vertebrate Brain Specific Splicing Program
  44. Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
  45. Diquat causes caspase-independent cell death in SH-SY5Y cells by production of ROS independently of mitochondria
  46. Rapid and equivalent systemic bioavailability of the antidotes HI-6 and dicobalt edetate via the intraosseous and intravenous routes
  47. Frontotemporal dementia and its subtypes: a genome-wide association study
  48. Intralobar fibres of the occipital lobe: A post mortem dissection study
  49. Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer’s disease
  50. White matter connections of the supplementary motor area in humans
  51. Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculopontine Nucleus in Parkinson Disease
  52. Variation in tau isoform expression in different brain regions and disease states
  53. A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
  54. Neuroferritinopathy
  55. Sex differences in effects of low level domoic acid exposure
  56. British Journal of Neurosurgery
  57. Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease
  58. Real-time monitoring of superoxide generation and cytotoxicity in neuroblastoma mitochondria induced by 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline
  59. FUS and TDP43 genetic variability in FTD and CBS
  60. Relationship Between Mitochondria and α-Synuclein
  61. Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project
  62. Synaptic Protein Alterations in Parkinson’s Disease
  63. Cellular pathology within the anterior cingulate cortex of patients with late-life depression: A morphometric study
  64. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
  65. Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death
  66. Any old iron?
  67. NOS3 gene rs1799983 polymorphism and incident dementia in elderly stroke survivors
  68. Morphometric Analysis of Neuronal and Glial Cell Pathology in the Caudate Nucleus in Late-Life Depression
  69. Examination of glucose transporter-1, transforming growth factor-β and neuroglobin immunoreactivity in the orbitofrontal cortex in late-life depression
  70. Mitochondrial Dysfunction in Parkinson's Disease
  71. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions
  72. The immunhistochemical examination of GABAergic interneuron markers in the dorsolateral prefrontal cortex of patients with late-life depression
  73. A morphometric examination of neuronal and glial cell pathology in the orbitofrontal cortex in late-life depression
  74. cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases
  75. Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene
  76. The low abundance of clonally expanded mitochondrial DNA point mutations in aged substantia nigra neurons
  77. Morphometric analysis of neuronal and glial cell pathology in the dorsolateral prefrontal cortex in late-life depression
  78. BuChE-K and APOE ϵ4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline
  79. Nature of Mitochondrial DNA Deletions in Substantia Nigra Neurons
  80. Decreased Fractalkine and Increased IP-10 Expression in Aged Brain of APPswe Transgenic Mice
  81. Common genetic variation within the Low-Density Lipoprotein Receptor-Related Protein 6 and late-onset Alzheimer's disease
  82. Individual dopaminergic neurons show raised iron levels in Parkinson disease
  83. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts
  84. Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL
  85. Soluble cell adhesion molecules in late-life depression
  86. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients
  87. Apolipoprotein  3 allele is associated with persistent hepatitis C virus infection
  88. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease
  89. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia
  90. Does the mitochondrial genome play a role in the etiology of Alzheimer’s disease?
  91. A Scan of Chromosome 10 Identifies a Novel Locus Showing Strong Association with Late-Onset Alzheimer Disease
  92. Genetic Variability in CHMP2B and Frontotemporal Dementia
  93. Looking for biogenic magnetite in brain ferritin using NMR relaxometry
  94. Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling
  95. Impact of Hypertension and Apolipoprotein E4 on Poststroke Cognition in Subjects >75 Years of Age
  96. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease
  97. Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme
  98. Angiotensin converting enzyme insertion/deletion polymorphisms in vasovagal syncope
  99. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration
  100. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation
  101. Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis
  102. Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease
  103. APOA1 polymorphism influences risk for early-onset nonfamiliar AD
  104. Familial neurocardiogenic (vasovagal) syncope
  105. Increase in Interleukin-1β in Late-Life Depression
  106. The K Variant of the Butyrylcholinesterase Gene Is Associated with Reduced Phosphorylation of Tau in Dementia Patients
  107. Correction: no evidence of an association between the T16189C mtDNA variant and late onset dementia (Gibson et al)
  108. High throughput approaches in neuroscience
  109. APOE  4 and cognitive decline in older stroke patients with early cognitive impairment
  110. Dementia with Lewy bodies: no association of polymorphisms in the human synphilin gene
  111. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies
  112. Influence of the amyloid precursor protein locus on dementia in Down syndrome
  113. Functional genomics and proteomics: application in neurosciences
  114. Novel presenilin 1 mutation with profound neurofibrillary pathology in an indigenous Southern African family with early-onset Alzheimer's disease
  115. Polymorphism in the human DJ-1 gene is not associated with sporadic dementia with Lewy bodies or Parkinson's disease
  116. Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double-stranded RNA
  117. Cognitive Decline in Down Syndrome—Reply
  118. Regulation of attention and response to therapy in dementia by butyrylcholinesterase
  119. Cholinesterase inhibitors in the treatment of dementia
  120. Dementia with Lewy bodies
  121. Neuroferritinopathy: A Window on the Role of Iron in Neurodegeneration
  122. The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease
  123. Selective Nicotinic Receptor Consequences in APPSWE Transgenic Mice
  124. Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice
  125. Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies
  126. Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans
  127. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease
  128. No pathogenic mutations in the synphilin-1 gene in Parkinson's disease
  129. Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies
  130. Is apolipoprotein e4 associated with cognitive decline in depression?
  131. Parkinson's disease is not associated with the combined ?-synuclein/apolipoprotein E susceptibility genotype
  132. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease
  133. Neuritogenic-Neurotoxic Effects of Membrane-Associated Forms ofAmyloid Precursor Prot ein
  134. Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease
  135. Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies
  136. Non-Alzheimer dementias
  137. Brain oestradiol and testosterone levels in Alzheimer's disease
  138. Distribution of Amyloid beta42 in Relation to the Cerebral Microvasculature in an Elderly Cohort with Alzheimer's Disease
  139. Hereditary Vascular Dementia Linked to Notch 3 Mutations: CADASIL in British Families
  140. The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies
  141. Risk for Alzheimer's disease in older late-onset cases is associated with HLA-DRB1*03
  142. Aberrant Splicing in the Presenilin-1 Intron 4 Mutation Causes Presenile Alzheimer's Disease by Increased A 42 Secretion
  143. Apolipoprotein E ϵ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias
  144. α2-Macroglobulin polymorphisms in Alzheimerʼs disease and dementia with Lewy bodies
  145. Frequency of HLA-A and B alleles in early and late-onset Alzheimer's disease
  146. Diagnosis of Mitochondrial Disease: Assessment of Mitochondrial DNA Heteroplasmy in Blood
  147. LRP gene and late-onset Alzheimer's disease
  148. Butyrylcholinesterase K: an association with dementia with Lewy bodies
  149. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use
  150. Neuroblastoma and Alzheimer’s Disease Brain Cells Contain Aromatase Activity
  151. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease
  152. Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population
  153. Apolipoprotein E and alpha-1 antichymotrypsin polymorphism genotyping in Alzheimer's disease and in dementia with Lewy bodies Distinctions between diseases
  154. D2 dopamine receptor gene (DRD2) Taql A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele
  155. No association between a polymorphism in the presenilin 1 gene and dementia with Lewy bodies
  156. No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer's disease
  157. Presenilin polymorphisms in Alzheimer's disease
  158. HLA-DR antigens associated with major genetic risk for late-onset Alzheimerʼs disease
  159. Effect of aluminium on expression and processing of amyloid precursor protein
  160. Apolipoprotein E genotyping in Alzheimer's disease
  161. Apolipoprotein E Genotype and Alzheimer's Disease in an Elderly Norwegian Cohort
  162. Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians
  163. Effects of Apolipoprotein E Genotype on Cortical Neuropathology in Senile Dementia of the Lewy Body and Alzheimer's Disease
  164. The role of the cholinergic system in the development of the human cerebellum
  165. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology
  166. Distribution of Nicotinic Receptors in the Human Hippocampus and Thalamus
  167. Transferrin receptors in the Parkinsonian midbrain
  168. Transferrin receptors in the normal human hippocampus and in Alzheimer's disease
  169. Protective effect of apoE ∈2 in Alzheimer's disease
  170. Distribution of neuronal nicotinic receptor subunits in human brain
  171. Apolipoprotein E genes in Lewy body and Parkinson's disease
  172. Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus
  173. Iron uptake in the brain of the myelin-deficient rat
  174. Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia
  175. Evidence for the localization of haemopexin immunoreactivity in neurones in the human brain
  176. Hippocampal p75 Nerve Growth Factor Receptor Immunoreactivity in Development, Normal Aging and Senescence
  177. Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients
  178. Distribution of transferrin receptors in relation to cytochrome oxidase activity in the human spinal cord, lower brainstem and cerebellum
  179. Brain iron homeostasis
  180. Hippocampal nerve growth factor receptor immunoreactivity in patients with Alzheimer's and Parkinson's disease
  181. Uptake and Distribution of Iron and Transferrin in the Adult Rat Brain
  182. Immunocytochemical Localisation of Transferrin in the Human Brain
  183. Nerve Growth Factor Receptor-like Immunoreactivity in the Human Spinal Cord
  184. The imaging and quantification of aluminium in the human brain using dynamic secondary ion mass spectrometry (SIMS)
  185. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases
  186. Transferrin-gallium binding in Alzheimer's disease
  187. Laterality and 5HT2 receptors in human brain
  188. Distribution of nerve growth factor receptor immunoreactivity in the human hippocampus
  189. Brain transferrin receptors and the distribution of cytochrome oxidase
  190. Gallium-67 as a Potential Marker for Aluminium Transport in Rat Brain: Implications for Alzheimer's Disease
  191. Gallium-transferrin binding in Alzheimer disease
  192. Comparison of the regional distribution of transferrin receptors and aluminium in the forebrain of chronic renal dialysis patients
  193. Comparison of the regional distribution of transferrin receptors and aluminium in the forebrain of chronic renal dialysis patients
  194. Interaction between metal ions and neuroleptics